BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...degeneration (AMD).The precision medicine approach to kidney diseases is also gaining momentum. Companies such as Goldfinch Biopharma...
BioCentury | Jul 1, 2020
Finance

Data Bytes: Venture megarounds tracking to new record

Goldfinch Bio Inc. has raised the forty-seventh megaround of the year, putting the biotech sector on pace to close 92 venture financings of $100 million or more. That would be a 61% increase compared with...
BioCentury | Jul 1, 2020
Finance

Goldfinch’s $100M round sets up Third Rock company to advance kidney disease therapies

...With $100 million in series B funding, Goldfinch Bio Inc. aims to move its second kidney disease therapy...
...subfamily C member 5 CB1 (CNR1) - Cannabinoid receptor 1 Elizabeth S. Eaton, Staff Writer Eventide Asset Management Goldfinch Bio Inc. chronic...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Ostrowski, who left the antibiotics company in December 2018. Donaldson was VP of finance at Goldfinch Bio Inc....
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

...where it’s needed, and only affecting complement dysfunction in diseased tissue.” Broxson was CBO at Goldfinch Bio Inc....
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...of software engineering. He was VP of software engineering, product development at Illumina Inc. (NASDAQ:ILMN). Goldfinch Bio Inc....
...Biohub Grail Inc. PMV Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. Gritstone Oncology Inc. PCI Biotech Holding ASA Progenity Inc. VIB Reistone Biopharma Co. Ltd. Galecto Inc. Goldfinch Bio Inc. Johnson...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...licensing fees. Details are not disclosed. Goldfinch licenses CB1 inhibitor for kidney diseases from Takeda Goldfinch Biopharma...
...Associate Editor Viaskin Peanut (DBV-712) Editas Medicine Inc. MaxCyte Inc. Takeda Pharmaceutical Co. Ltd. Prometheus Biosciences Inc. DBV Technologies S.A. Galderma Laboratories L.P. Goldfinch Bio Inc. CFB-024 Aklief...
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...Inc. with a $65 million series A round. Three months earlier, kidney-focused precision medicine startup, Goldfinch Biopharma...
...member 5 V2 receptor - Vasopressin 2 receptor Lauren Martz, Associate Editor Chinook Therapeutics Inc. Versant Ventures Palladio Biosciences Inc. Goldfinch Bio Inc. ZyVersa...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...As further evidence, he pointed to a May deal between Gilead Sciences Inc. (NASDAQ:GILD) and Goldfinch Biopharma...
BioCentury | Jul 10, 2019
Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

...Additionally, in May, Gilead Sciences Inc. (NASDAQ:GILD) entered the kidney space via a deal with Goldfinch Biopharma...
Items per page:
1 - 10 of 18
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...degeneration (AMD).The precision medicine approach to kidney diseases is also gaining momentum. Companies such as Goldfinch Biopharma...
BioCentury | Jul 1, 2020
Finance

Data Bytes: Venture megarounds tracking to new record

Goldfinch Bio Inc. has raised the forty-seventh megaround of the year, putting the biotech sector on pace to close 92 venture financings of $100 million or more. That would be a 61% increase compared with...
BioCentury | Jul 1, 2020
Finance

Goldfinch’s $100M round sets up Third Rock company to advance kidney disease therapies

...With $100 million in series B funding, Goldfinch Bio Inc. aims to move its second kidney disease therapy...
...subfamily C member 5 CB1 (CNR1) - Cannabinoid receptor 1 Elizabeth S. Eaton, Staff Writer Eventide Asset Management Goldfinch Bio Inc. chronic...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Ostrowski, who left the antibiotics company in December 2018. Donaldson was VP of finance at Goldfinch Bio Inc....
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

...where it’s needed, and only affecting complement dysfunction in diseased tissue.” Broxson was CBO at Goldfinch Bio Inc....
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...of software engineering. He was VP of software engineering, product development at Illumina Inc. (NASDAQ:ILMN). Goldfinch Bio Inc....
...Biohub Grail Inc. PMV Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. Gritstone Oncology Inc. PCI Biotech Holding ASA Progenity Inc. VIB Reistone Biopharma Co. Ltd. Galecto Inc. Goldfinch Bio Inc. Johnson...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...licensing fees. Details are not disclosed. Goldfinch licenses CB1 inhibitor for kidney diseases from Takeda Goldfinch Biopharma...
...Associate Editor Viaskin Peanut (DBV-712) Editas Medicine Inc. MaxCyte Inc. Takeda Pharmaceutical Co. Ltd. Prometheus Biosciences Inc. DBV Technologies S.A. Galderma Laboratories L.P. Goldfinch Bio Inc. CFB-024 Aklief...
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...Inc. with a $65 million series A round. Three months earlier, kidney-focused precision medicine startup, Goldfinch Biopharma...
...member 5 V2 receptor - Vasopressin 2 receptor Lauren Martz, Associate Editor Chinook Therapeutics Inc. Versant Ventures Palladio Biosciences Inc. Goldfinch Bio Inc. ZyVersa...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...As further evidence, he pointed to a May deal between Gilead Sciences Inc. (NASDAQ:GILD) and Goldfinch Biopharma...
BioCentury | Jul 10, 2019
Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

...Additionally, in May, Gilead Sciences Inc. (NASDAQ:GILD) entered the kidney space via a deal with Goldfinch Biopharma...
Items per page:
1 - 10 of 18